Author

Carolina Palmela

SEVERE COLITIS FOLLOWING RITUXIMAB THERAPY: A RARE ENTITY
SEVERE COLITIS FOLLOWING RITUXIMAB THERAPY: A RARE ENTITY

Carolina Palmela  et al.

LYNCH SYNDROME - BEYOND THE COLON
LYNCH SYNDROME - BEYOND THE COLON

Carolina Palmela  et al.

INEFFECTIVE ESOPHAGEAL MOTILITY: IS SEVERE COMPROMISE RELEVANT?
INEFFECTIVE ESOPHAGEAL MOTILITY: IS SEVERE COMPROMISE RELEVANT?

Carolina Palmela  et al.

HEPATITIS B REACTIVATION DURING HEPATITIS C TREATMENT
HEPATITIS B REACTIVATION DURING HEPATITIS C TREATMENT

Carolina Palmela  et al.

USE OF LIVER TRANSIENT ELASTOGRAPHY ON THE PREDICTION OF THE PRESENCE OF OESOPHAGEAL VARICES IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE: IS THE AETIOLOGY RELEVANT?
USE OF LIVER TRANSIENT ELASTOGRAPHY ON THE PREDICTION OF THE PRESENCE OF OESOPHAGEAL VARICES IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE: IS THE AETIOLOGY RELEVANT?

Carolina Palmela  et al.

SECONDARY SCLEROSING CHOLANGITIS IN A CRITICALLY-ILL PATIENT PRECIPITATED BY SARS-COV2 INFECTION
SECONDARY SCLEROSING CHOLANGITIS IN A CRITICALLY-ILL PATIENT PRECIPITATED BY SARS-COV2 INFECTION

Carolina Palmela  et al.

NBI FOR THE DETECTION OF SESSILE SERRATED LESIONS: A RANDOMIZED CONTROLLED TRIAL
NBI FOR THE DETECTION OF SESSILE SERRATED LESIONS: A RANDOMIZED CONTROLLED TRIAL

Carolina Palmela  et al.

WHAT IS THE REAL IMPACT OF THE HLA-DQA1*05 POLYMORPHISM ON INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?
WHAT IS THE REAL IMPACT OF THE HLA-DQA1*05 POLYMORPHISM ON INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?

Carolina Palmela  et al.

ABC SCORE TO PREDICT LOWER GASTROINTESTINAL BLEEDING SEVERITY: A STEP IN THE RIGHT DIRECTION
ABC SCORE TO PREDICT LOWER GASTROINTESTINAL BLEEDING SEVERITY: A STEP IN THE RIGHT DIRECTION

Carolina Palmela  et al.

MAINTENANCE THERAPY AFTER AN EPISODE OF STEROID-RESPONSIVE ACUTE SEVERE ULCERATIVE COLITIS: WHAT IS THE BEST STRATEGY?
MAINTENANCE THERAPY AFTER AN EPISODE OF STEROID-RESPONSIVE ACUTE SEVERE ULCERATIVE COLITIS: WHAT IS THE BEST STRATEGY?

Carolina Palmela  et al.

EARLY INTERVENTION WITH BIOLOGICS IN CROHN'S DISEASE - HOW EARLY IS EARLY?
EARLY INTERVENTION WITH BIOLOGICS IN CROHN'S DISEASE - HOW EARLY IS EARLY?

Carolina Palmela  et al.

USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE
USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE

Carolina Palmela  et al.

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION
INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION

Carolina Palmela  et al.

Item 1 - 13 / 13
1